Nanjing Vazyme Biotech Co (SHSE:688105) Cash-to-Debt : 2.81 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nanjing Vazyme Biotech Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nanjing Vazyme Biotech Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.81.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nanjing Vazyme Biotech Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Nanjing Vazyme Biotech Co's Cash-to-Debt or its related term are showing as below:

SHSE:688105' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.63 Med: 7.12 Max: 37.88
Current: 2.81

During the past 7 years, Nanjing Vazyme Biotech Co's highest Cash to Debt Ratio was 37.88. The lowest was 2.63. And the median was 7.12.

SHSE:688105's Cash-to-Debt is ranked worse than
61.6% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs SHSE:688105: 2.81

Nanjing Vazyme Biotech Co Cash-to-Debt Historical Data

The historical data trend for Nanjing Vazyme Biotech Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nanjing Vazyme Biotech Co Cash-to-Debt Chart

Nanjing Vazyme Biotech Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.63

22.42

37.88

7.12

2.71

Nanjing Vazyme Biotech Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															3.20	2.66	2.64	2.71	2.81

Competitive Comparison of Nanjing Vazyme Biotech Co's Cash-to-Debt

For the Biotechnology subindustry, Nanjing Vazyme Biotech Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Vazyme Biotech Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanjing Vazyme Biotech Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nanjing Vazyme Biotech Co's Cash-to-Debt falls into.

Nanjing Vazyme Biotech Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nanjing Vazyme Biotech Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3480.887	/	(1180.126	+	106.891)
	=	2.70

Nanjing Vazyme Biotech Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3044.117	/	(934.917	+	147.287)
	=	2.81

Nanjing Vazyme Biotech Co (SHSE:688105) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nanjing Vazyme Biotech Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nanjing Vazyme Biotech Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Vazyme Biotech Co (SHSE:688105) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanjing Vazyme Biotech Co Ltd (SHSE:688105) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000

Website

http://www.vazyme.com

Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.

Nanjing Vazyme Biotech Co (SHSE:688105) Headlines

No Headlines